Post-earnings recap
Reported
Wed, Jul 29, 2015
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Neurocrine Biosciences reported a narrower-than-expected loss per share, which was a positive surprise for investors. However, the stock fell by 2.43%, likely due to the lack of revenue figures and updated guidance. Investors may be concerned about the company's future performance without clear direction from management.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.28 | N/A | +3.45% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a cautious optimism about future developments. However, they did not provide updated guidance for the upcoming quarters.
Management expressed confidence in the company's long-term strategy.
They highlighted ongoing efforts to advance their pipeline.
No specific updates on revenue guidance were provided.